Paper8530489
Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor.
Montgomery RB and 4 others. J Biol Chem, 1995. Cited by 80 papers, by iCite.
Cite this record
ConductScience Library. Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. Papers, record 8530489. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8530489
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Differential modulation of mitogen-activated protein (MAP) kinase/extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor.
- PubMed
- Publication types
- Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Calcium-Calmodulin-Dependent Protein Kinases | Major topic |
| ErbB Receptors | Major topic |
| Protein Kinases | Major topic |
| Sequence Deletion | Major topic |
| 3T3 Cells | |
| Animals | |
| Enzyme Activation | |
| Epidermal Growth Factor | |
| Glioblastoma | |
| Humans | |
| Kinetics | |
| Mice | |
| Mitogen-Activated Protein Kinase Kinases | |
| Recombinant Proteins | |
| Tetradecanoylphorbol Acetate | |
| Transfection | |
| Tumor Cells, Cultured | |
| Vanadates |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 60782-01 | NCI NIH HHS | United States | PubMed | PubMed | |
| K08CA060782 | NIH | NIH RePORTER |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 80 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41565660 | An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression. | Nat Commun | 2026 | https://conductscience.org/library/papers/41565660 | PubMed |
| 37368466 | Mass Spectrometry and Pharmacological Approaches to Measuring Cooption and Reciprocal Activation of Receptor Tyrosine Kinases. | Proteomes | 2023 | https://conductscience.org/library/papers/37368466 | PubMed |
| 28745721 | Helping EGFR inhibition to block cancer. | Nat Neurosci | 2017 | https://conductscience.org/library/papers/28745721 | PubMed |
| 28629170 | EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28629170 | PubMed |
| 27030122 | Extracellular ATP protects endothelial cells against DNA damage. | Purinergic Signal | 2016 | https://conductscience.org/library/papers/27030122 | PubMed |
| 25885672 | Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma. | Cell Commun Signal | 2015 | https://conductscience.org/library/papers/25885672 | PubMed |
| 25434384 | Molecularly targeted therapies for recurrent glioblastoma: current and future targets. | Neurosurg Focus | 2014 | https://conductscience.org/library/papers/25434384 | PubMed |
| 23429996 | EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. | Acta Neuropathol | 2013 | https://conductscience.org/library/papers/23429996 | PubMed |
| 22751114 | Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo. | Oncogene | 2013 | https://conductscience.org/library/papers/22751114 | PubMed |
| 22490227 | Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22490227 | PubMed |
| 20472883 | mTOR signaling in glioblastoma: lessons learned from bench to bedside. | Neuro Oncol | 2010 | https://conductscience.org/library/papers/20472883 | PubMed |
| 20461251 | Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. | Mol Biosyst | 2010 | https://conductscience.org/library/papers/20461251 | PubMed |
| 19588487 | EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. | Int J Cancer | 2009 | https://conductscience.org/library/papers/19588487 | PubMed |
| 19560740 | Targeted therapy for malignant glioma patients: lessons learned and the road ahead. | Neurotherapeutics | 2009 | https://conductscience.org/library/papers/19560740 | PubMed |
| 19542748 | Mutant epidermal growth factor receptor vIII increases cell motility and clonogenecity in a prostate cell line RWPE1. | J Endocrinol Invest | 2009 | https://conductscience.org/library/papers/19542748 | PubMed |
| 18812521 | EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. | Neuro Oncol | 2009 | https://conductscience.org/library/papers/18812521 | PubMed |
| 18628764 | The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. | Br J Cancer | 2008 | https://conductscience.org/library/papers/18628764 | PubMed |
| 18459149 | Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. | J Cell Biochem | 2008 | https://conductscience.org/library/papers/18459149 | PubMed |
| 18288481 | Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. | Histochem Cell Biol | 2008 | https://conductscience.org/library/papers/18288481 | PubMed |
| 16464404 | Correlative studies in neuro-oncology trials: should they influence treatment? | Curr Oncol Rep | 2006 | https://conductscience.org/library/papers/16464404 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CDK20 | 23552 | PubTator's text mining | https://conductscience.org/library/genes/23552 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| GRB2 | 2885 | PubTator's text mining | https://conductscience.org/library/genes/2885 | NCBI Gene |
| IFI44 | 10561 | PubTator's text mining | https://conductscience.org/library/genes/10561 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8530489
GET https://conductscience.org/api/papers/v1/8530489/cited_by?page=2